1001070-23-0

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 6-bromo-1-(phenylsulfonyl)-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 6-bromo-1-(phenylsulfonyl)-;1-(Phenylsulphonyl)-6-broMo-7-azaindole;1-(phenylsulfonyl)-6-bromo-7-azaindole;1-(benzenesulfonyl)-6-bromopyrrolo[2,3-b]pyridine
• CAS NO: 1001070-23-0
• Molecular Formula: C₁₃H₉BrN₂O₂S
• Molecular Weight: 337.19176
• Mol File: 1001070-23-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 6-bromo-1-(phenylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 6-bromo-1-(phenylsulfonyl)-(1001070-23-0)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 6-bromo-1-(phenylsulfonyl)-(1001070-23-0)

Safety Data

• Hazardous Substances Data: 1001070-23-0(Hazardous Substances Data)

Usage

Structure

The compound has a unique structure consisting of a pyrrolopyridine ring with a bromino substitution at the 6th position and a phenylsulfonyl group attached at the 1st position.

Potential pharmaceutical applications

The compound has potential pharmaceutical applications due to its interesting structural features and potential biological activities.

Chemical and pharmacological properties

The bromine substitution and the phenylsulfonyl group may impart specific chemical and pharmacological properties to the compound.

Scaffold for synthesis

The presence of the pyrrolopyridine ring in the structure provides opportunities for diverse chemical transformations and potential biological activities, making it a valuable scaffold for the synthesis of novel drug candidates.

Upstream product

• 143468-13-7 6-Bromo-1H-pyrrolo<2,3-b>pyridine 
• 98-09-9 benzenesulfonyl chloride 

Relevant articles and documents

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

(AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

7-Azaindole derivatives as potential partial nicotinic agonists

We have investigated a series of 7-azaindoles as potential partial agonists of the α4β2 nicotinic acetylcholine receptor (nAChR). Three series of 7-azaindole derivatives have been synthesized and evaluated for rat brain neuronal nicotinic receptor affinity and functional activity. Compound (+)-51 exhibited the most potent nAChR binding (Ki = 10 nM). Compound 30A demonstrated both moderate binding affinity and partial agonist potency, thus representing a promising lead for the indications of cognition and smoking cessation.

AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION

Azaindole derivatives of formula (I): wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors